SGLT2 inhibitors were associated with 26% lower risk of HF hospitalisation than other oral and injectable glucose-lowering drugs (HR 0.74; 95% CI 0.69, 0.80) [55]. The gene discussed is SLC5A2; the disease is hydrops fetalis.